OKT3 induction therapy: Influence of duration on rejections and infections

Clinical Transplantation

Volumn 10, Issue 6 II, 1996, Pages 614-616

  Zibari, G B ^a   Boykin, K N ^a   Thomas, J P ^a   Aultman, D F ^a   Aradhye, S A ^a   McMillan, R W ^a   McDonald, J C ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Induction; OKT3; Renal transplant

Indexed keywords

MONOCLONAL ANTIBODY; OKT 3;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0030452052     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. SCHWEITZER ET, MATAS AJ, GILLINGHAM KJ. et al. Causes of renal allograft loss. Ann Surg 1991: 214: 679.
2. ORTHO MULTICENTER TRANSPLANT STUDY GROUP. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985: 313.
3. GOLDSTEIN G. An overview of Orthoclone OKT3. Transpl Proc 1986: 18: 927.
4. DEIERHOI MH, BARBER WH, CURTIS JJ, et al. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. Am J Kidney Dis 1988 11: 86.
5. COSIMI AB, BURTON RC, COLVTN RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981: 32: 535.
6. NORMAN DJ, KAHANA L, STUART FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993: 55: 44.
7. NORMAN DJ, SHIELD CF, BARRY J. et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kidney Dis 1988 11: 107.
8. TODD PA, BROGDEN RN. Muromonab CD3: a review of its pharmacology and therapeutic potential. Drugs 1989: 37: 871.
9. ALLOWAY R, KOTB M, HATHAWAY DK, GABER LW, VERA SR, GABER AO. Randomized double-blind study of standard versus low-dose OKT3 induction therapy in renal allograft recipients. Am J Kidney Dis 1993: 22: 36.
10. ALLOWAY R. KOTB M, HATHAWAY DK, GABER LW, VERA SR, GABER AO. Results of a prospective, randomized double-blind study comparing standard vs. low-dose OKT3 induction therapy Transpl Proc 1993: 25: 550.
11. NORMAN DJ, BARRY JM, BENNETT WM, et al. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses. Transpl Proc 1991: 23: 1052.